@article {7575,
	title = {Primary therapy of Waldenstr{\"o}m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): Long-term results of a phase 2 study of the European Myeloma Network (EMN)},
	journal = {Blood},
	volume = {122},
	year = {2013},
	note = {Cited By :40Export Date: 21 February 2017},
	month = {2013},
	pages = {3276 - 3282},
	abstract = {In this phase 2 multicenter trial, we evaluated the activity of bortezomib, dexamethasone, and rituximab (BDR) combination in previously untreated symptomatic patients with Waldenstr{\"o}m macroglobulinemia (WM). To prevent immunoglobulin M (IgM) "flare," single agent bortezomib (1.3 mg/m 2 IV days 1, 4, 8, and 11;21-day cycle), was followed by weekly IV bortezomib (1.6 mg/m2 days 1, 8, 15, and 22) every 35 days for 4 additional cycles, followed by IV dexamethasone (40 mg) and IV rituximab (375 mg/m2) in cycles 2 and 5. Fifty-nine patients were treated; 45.5\% and 40\% were high and intermediate risk per the International Prognostic Scoring System for WM. On intent to treat, 85\% responded (3\% complete response, 7\% very good partial response, 58\% partial response [PR]).In 11\% of patients, an increase of IgM >=25\% was observed after rituximab; no patient required plasmapheresis. After a minimum follow-up of 32 months, median progression-free survival was42months, 3-year durationof response for patients with>=PR was 70\%, and 3-year survival was 81\%. Peripheral neuropathy occurred in 46\% (grade >=3 in 7\%); only 8\% discontinued bortezomib due to neuropathy. BDR is rapidly acting, well tolerated, and nonmyelotoxic, inducing durable responses in previously untreated WM. {\textcopyright} 2013 by The American Society of Hematology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84888260930\&doi=10.1182\%2fblood-2013-05-503862\&partnerID=40\&md5=35085bb5f66d1631984f110dea949f7e},
	author = {Dimopoulos, M.A. and Gar{\'c}ia-Sanz, R. and Gavriatopoulou, M. and Morel, P. and Kyrtsonis, M.-C. and Michalis, E. and Kartasis, Z. and Leleu, X. and Palladini, G. and Tedeschi, A. and Gika, D. and Merlini, G. and Kastritis, E. and Sonneveld, P.}
}
